AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06295120
Drug: Phenoxymethylpenicillin 1.2 MIE 4 times daily
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention is the duration of treatment with phenoxymethylpenicillin from 3 to 7 days. Dose and frequency of the treatment is the same in the different arms.
Trial: NCT06570915
Drug: Daratumumab Injection
RxNorm normalized name: daratumumab Injection
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab was administered once a week at a dose of 16 mg/kg for a total of 4 times (Day1,8,15,22 ) in one cycle.
Trial: NCT06319274
Drug: Iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min
Trial: NCT06501339
Drug: Aripiprazole tablet
RxNorm normalized name: Aripiprazole Tablets
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole 10 mg in the morning throughout the study period
Trial: NCT05205720
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mixed solution for nerve block, made of 0.75% ropivacaine (Naropin, Astrazeneca AB) diluted in different proportions.
Trial: NCT04818086
Drug: Lemborexant
RxNorm normalized name: Lemborexant
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will complete 2 inpatient visits which may last up to 24 hours. The two visits will be approximately 14 days apart. During the inpatient visit they will receive 5 mg of lemborexant (first visit) and 10 mg of lemborexant (second visit).
Trial: NCT04818086
Drug: Buprenorphine-naloxone
RxNorm normalized name: Buprenorphine-Naloxone
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive 16 mg/4 mg of buprenorphine-naloxone sublingually as a film.
Trial: NCT05454891
Drug: Extended bolus of insulin then standard bolus of insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For a standardized HFHP breakfast, participants will receive an extended meal bolus of insulin on the first morning and a standard meal bolus of insulin on the second morning of the study.
Trial: NCT05454891
Drug: Standard bolus of insulin then extended bolus of insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For a standardized HFHP breakfast, participants will receive a standard bolus of insulin on the first morning and an extended bolus of insulin on the second morning of the study.
Trial: NCT06250257
Drug: Bromocriptine mesylate plus standard GDMT
RxNorm normalized name: Bromocriptine Mesylate
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treatment group will receive bromocriptine 2.5mg PO daily for 8 weeks together with standard GDMT which include similar patterns of BBs, ACEI/ARBs, MRAs and SGLT2 inhibitors.
Trial: NCT06393985
Drug: Decitabine, venetoclax and blinatumomab
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycle1 and cycle3： Decitabine monotherapy,20 mg/m2 qd, d1-5,intravenous infusion;~Cycle2 and cycle4:~Venetoclax 200mg qd, d1-14, orally; Blinatumomab d4-17(Weight ≥45 kg, 9ug d4-6, 28ug d7-17; Weight \<45 kg, 5ug/m2 d4-6, 15ug/m2 d7-17;continuous intravenous infusion)
Trial: NCT05444088
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT05444088
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravenous infusion
Trial: NCT05444088
Drug: SHR-8068
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT05782244
Drug: Sildenafil Citrate low dose
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate 20 mg, oral, TID
Trial: NCT05782244
Drug: Sildenafil medium dose
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil 40 mg, oral, TID
Trial: NCT05782244
Drug: Sildenafil high dose
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil 80 mg, oral, TID
Trial: NCT05065671
Drug: Tolcapone 100 MG
RxNorm normalized name: tolcapone 100 MG
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolcapone 100 mg by mouth once
Trial: NCT05065671
Drug: Duloxetine 20 MG
RxNorm normalized name: duloxetine 20 MG
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duloxetine 20 mg by mouth once
Trial: NCT06530303
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.
Trial: NCT06530303
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
Trial: NCT06530303
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) infusion
Trial: NCT04636437
Drug: Doravirine 100 Mg
RxNorm normalized name: doravirine 100 MG
DrugBank: Doravirine (DB12301)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 100 mg tablet by mouth daily with or without food.
Trial: NCT04636437
Drug: Tenofovir alafenamide/emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
Trial: NCT04636437
Drug: tenofovir alafenamide/lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
Trial: NCT04636437
Drug: tenofovir disproxil fumarate/emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
Trial: NCT04636437
Drug: tenofovir disproxil fumarate/lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NRTIs for all arms (TAF/FTC, TAF/3TC, TDF/FTC, or TDF/3TC) and INSTIs for Arm 3 will be acquired through standard of care locally.
Trial: NCT05431088
Drug: Osivelotor
RxNorm normalized name: Osivelotor
DrugBank: Osivelotor (DB18071)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets which contain drug substance
Trial: NCT05696782
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive Durvalumab 1500 mg intravenously every two weeks for 60 minutes. Each treatment is called a cycle and lasts for four weeks (or 28 days).
Trial: NCT05378425
Drug: NTX-1088
RxNorm normalized name: NTx-265
DrugBank: NTx-265 (DB05649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG4 mAb targeting the poliovirus receptor (PVR, CD155).
Trial: NCT05378425
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
Trial: NCT04791020
Drug: Lidocaine topical
RxNorm normalized name: lidocaine topical
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mL of lidocaine gel applied topically to cervix previous to clamping, No paracervical blockade will be applied.
Trial: NCT06004674
Drug: Lovenox 40mg
RxNorm normalized name: Lovenox 40mg/0.4ml Solution for Injection
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin is a blood thinner. It is approved for use in the prevention of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness; inpatient treatment of acute DVT with or without pulmonary embolism; outpatient treatment of acute DVT without pulmonary embolism; Prevention of ischemic complications of unstable angina and non-Q-wave myocardial infarction; treatment of acute ST-segment elevation myocardial infarction(STEMI) managed medically or with subsequent percutaneous coronary intervention. The use of Lovenox has been shown to be safe, and it has also been used widely off-label in pregnancy.
Trial: NCT05026632
Drug: NPI-002 Intravitreal Implant
RxNorm normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Implant inserted during vitrectomy.
Trial: NCT05156814
Drug: Duphaston
RxNorm normalized name: Duphaston
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duphaston®, 10 mg
Trial: NCT05156814
Drug: Divigel
RxNorm normalized name: Divigel
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divigel, 0.1%
Trial: NCT05318560
Drug: Lidocaine 2% Injectable Solution
RxNorm normalized name: lidocaine 2% injectable solution
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: for MPS
Trial: NCT05318560
Drug: Ozone
RxNorm normalized name: OZONE
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for MPS
Trial: NCT06011889
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: treatment with etanercept in addition to NSAID treatment and/or classic Disease Modifying Antirheumatic Drugs
Trial: NCT06670521
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg methylprednisolone IV every 6 hours for 4 doses to reduce laryngeal edema
Trial: NCT05700422
Drug: Varenicline Nasal Spray
RxNorm normalized name: varenicline Nasal Spray
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OC-01 (varenicline solution) 0.03 mg nasal spray
Trial: NCT06611813
Drug: Neoadjuvant Chemotherapy in Combination with Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (or Liposomal Doxorubicin)+Cyclophosphamide, intravenous infusion of 100 mg/m2. Epirubicin (or 35 mg/m2 liposomal doxorubicin)+600 mg/m2 cyclophosphamide, starting from the first day of the week, for a total of 12 weeks. Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks. During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant and postoperative adjuvant therapy for a total of 1 year.
Trial: NCT06611813
Drug: HR+ HER2 breast cancer
RxNorm normalized name: chicken breast preparation
DrugBank: Chicken (DB10519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During neoadjuvant chemotherapy and postoperative adjuvant therapy, use of Toripalimab: intravenous infusion of 240 mg, once every 3 weeks, combined with preoperative neoadjuvant therapy and postoperative adjuvant therapy for a total of 1 year.
Trial: NCT06676085
Drug: Nafamostat
RxNorm normalized name: Nafamostat
DrugBank: Nafamostat (DB12598)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Nafamostat combined with unfractionated heparin for anticoagulation
Trial: NCT05865886
Drug: BI 1291583
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1291583
Trial: NCT06675214
Drug: Cisplatin-based induction chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based induction chemotherapy will be given every 3 weeks for 3 cycles before radiotherapy.
Trial: NCT06675214
Drug: Concurrent Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100mg/m2 every 3 weeks for 2 cycles
Trial: NCT06689254
Drug: Mifepristone 1200 mg daily
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT05405166
Drug: Isatuximab IV
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: Concentrate solution for IV infusion; Route of administration: Intravenous
Trial: NCT05405166
Drug: Isatuximab SC
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: Solution for subcutaneous administration; Route of administration: Subcutaneous (SC)
Trial: NCT05405166
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Trial: NCT05405166
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: hard capsules; Route of administration: Oral
Trial: NCT05405166
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: As per local commercial product; Route of administration: Oral; Auxiliary Medicinal Product (AxMP) i.e., background treatment; ATC code: H02AB02
Trial: NCT05405166
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: R03DC03
Trial: NCT05405166
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: As per local commercial product; Route of administration: As premedication- oral; for management of infusion reactions-IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: R06AA02
Trial: NCT05405166
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: As per local commercial product; Route of administration: As premedication-IV; for management of infusion reactions- IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: H02AB04
Trial: NCT05137626
Drug: AT-527 + digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Day 1: A single dose of digoxin will be administered.~* Day 15: A single dose of AT-527 and digoxin will be co-administered.
Trial: NCT05137626
Drug: AT-527 + digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Day 1: A single dose of digoxin will be administered.~* Day 15: A single staggered dose of AT-527 and digoxin will be administered (2 hours later).
Trial: NCT04854499
Drug: Magrolimab
RxNorm normalized name: Magrolimab
DrugBank: Magrolimab (DB16225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT04854499
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously
Trial: NCT04854499
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT04854499
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT04854499
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT04854499
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT04854499
Drug: Zimberelimab
RxNorm normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT04921306
Drug: Clenbuterol Hydrochloride
RxNorm normalized name: Clenbuterol Hydrochloride
DrugBank: Clenbuterol (DB01407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 28 days with a wash-out period of at least 6-8 weeks.
Trial: NCT05818007
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The main function of HA appears to be in tissue healing, by activating and modulating inflammatory responses, stimulating cellular proliferation, migration, and angiogenesis, inducing basal keratinocyte proliferation and re-epithelization by reducing collagen deposition and scarring
Trial: NCT05818007
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sodium bicarbonate solution
Trial: NCT06569225
Drug: Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: : Patients will receive prior to surgery: 2 cycles of combinational therapy with Gemcitabine (800mg) /Cisplatin (25mg) /Nab-Paclitaxel (100mg) and Rilvegostomig (Q3W). Post-surgical resection, adjuvant therapy will consist of 4 cycles of Gemcitabine (1000mg) /Cisplatin (25mg) and Rilvegostomig (Q3W). Rilvegostomig (Q3W) will be continued for a total of 12 months in the adjuvant phase
Trial: NCT06571825
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The consolidation therapy involves a regimen of intermediate-dose cytarabine (Ara-C) combined with Ven, specifically Ara-C at 1.0 g/m²/day for 3 days (days 1-3) and Ven at 400 mg/day for 10 to 14 days (days 1-10 to 14), with each cycle lasting 4 to 6 weeks, for a total of 3 consolidation cycles. This is followed by maintenance therapy with azacitidine (AZA) at 50 mg/m²/day for 5 days (days 1-5), with each cycle lasting 4 weeks, for a total of 6 maintenance cycles.
Trial: NCT06571825
Drug: Allogeneic transplant
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The consolidation therapy involves allo-HSCT, with the choice of conditioning regimens typically using reduced-intensity conditioning such as the Fludarabine+Busulfan (FluBu) or Fludarabine+Melphalan (FluMel) regimens commonly used by centers, which can also include Ven.~FluBu regimen: Flu 30 mg/m²/day from day -10 to day -5, Bu 3.2 mg/kg/day from day -6 to day -5 or day -7 to day -5, antithymocyte globulin (ATG) (e.g., rabbit ATG at a total dose of 6-7.5 mg/kg, administered from day -4 to day -1), and Ven from day -10 to day -4.~FluMel regimen: Flu 30 mg/m²/day from day -10 to day -5, Mel 50-70 mg/m²/day from day -4 to day -3, ATG and Ven from day -10 to day -4.~12 weeks (±4 weeks) post-HSCT maintenance begins with AZA at 32 mg/m²/day for 5 days (days 1-5), with each lasting 6 weeks, for a total of 6 cycles. Donor lymphocyte infusion is allowed in cases of minimal residual disease (MRD) positivity.
Trial: NCT06632860
Drug: 68Ga-TATE-RGD
RxNorm normalized name: Gallium (68Ga) DOTA-tate
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 68Ga-TATE-RGD with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses will be used to image lesions of by dual-targeted postive cancers PET/CT.
Trial: NCT06632860
Drug: 18-FDG
RxNorm normalized name: 18-F FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 18F-FDG with the dosage of 1.8-2.2 MBq(0.12-0.15mCi/kg). Tracer doses will be used to lesions therapy of dual-targeted postive cancers by SPECT/CT.
Trial: NCT06530784
Drug: PD-1 antibody and bevacizumab
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Three days after cryoablation, the patients receive intravenous infusion of Tislelizumab (200mg, with 100mL of normal saline) and Bevacizumab (dose 15mg/kg, with 100mL of normal saline) .The patients will receive Tislelizumab (200 mg, with 100 mL of normal saline) and Bevacizumab (15 mg/kg, with 100 mL of normal saline) once every 3 weeks until disease progression.
Trial: NCT06045286
Drug: PD-1 Inhibitors
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (Zimberelimab) is given every three weeks within one week after the end of high-dose radiotherapy.
Trial: NCT04386239
Drug: Sarilumab Prefilled Syringe
RxNorm normalized name: sarilumab Prefilled Syringe
DrugBank: Sarilumab (DB11767)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sarilumab administration must be associated with an antiviral treatment as defined by the treatment protocol suggested by the SIMET Experts group 4 and AIFA recommendations: chloroquine 500 mg 1 tablet twice daily or hydroxychloroquine 400 mg 1 tablet twice daily in the first day and then 200 mg 1 tablet twice daily.
Trial: NCT04535362
Drug: Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: session will include 3 infusions in the same order: nicotine (1 mg per 70 kg body weight) delivered over 5 minutes, saline and nicotine (1 mg/ 70 kg) delivered over 2.5 minutes.